Skip to main content

Pharmacy solutions to deliver better health outcomes at a lower cost

Briefing

The CVS Caremark Guide: Member Affordability

The CVS Caremark Guide: Member Affordability provides an overview of how we provide pharmacy solutions that help deliver better health outcomes at a lower cost.

Read our report

 

Many promising new therapies are being developed every year, including gene and cell therapies, leading to a robust drug pipeline.

Our purpose — making health care more affordable and accessible — is what drives us to provide pharmacy solutions that help deliver better health outcomes at a lower cost.

29.3% reduction in member out-of-pocket costs over the past seven years1

Our new guide illustrates CVS Caremark’s approach to member affordability:

  • Creating flexible plan design options to help plan sponsors deliver the right solutions at the right cost
  • Empowering prescribers to see — and select — the most relevant, lower-cost alternatives based on members’ plans, helping them save right at the point of prescribing
  • Offering members real-time visibility into costs and equipping them with the tools to take their health (and health care costs) into their own hands

Delivering high-quality pharmacy benefits requires much more than just managing the dispensing of drugs. Check out the CVS Caremark Guide to Member Affordability to learn about all the ways we work to ensure members can experience better health outcomes with lower costs.

 

  • 1 The source for data in this document is CVS Health Enterprise Analytics, unless otherwise noted. Adherence results may vary based upon a variety of factors such as plan design, demographics and programs adopted by the plan. Client-specific modeling available upon request. Savings will vary based upon a variety of factors including things such as plan design, demographics and programs implemented by the plan. CVS Health uses and shares data as allowed by applicable law, and by our agreements and our information firewall.​ CVS Health Analytics, 2023.